Yanan Zhu
Stock Analyst at Wells Fargo
(4.52)
# 1,001
Out of 4,407 analysts
415
Total ratings
37.2%
Success rate
14.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics | Maintained: Buy | $70 | $29.03 | +141.13% | 22 | Jun 4, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Hold | $15 | $12.11 | +23.86% | 26 | May 12, 2026 | |
| MGX Metagenomi Therapeutics | Maintained: Buy | $12 → $9 | $1.20 | +650.00% | 14 | May 11, 2026 | |
| CYTK Cytokinetics | Maintained: Buy | $95 → $105 | $70.15 | +49.68% | 2 | May 7, 2026 | |
| SRPT Sarepta Therapeutics | Maintained: Buy | $38 | $15.31 | +148.20% | 15 | May 7, 2026 | |
| ONC BeOne Medicines AG | Maintained: Buy | $400 | $264.48 | +51.24% | 2 | May 7, 2026 | |
| ENGN enGene Therapeutics | Downgraded: Hold | $25 → $2 | $1.62 | +23.46% | 17 | May 7, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintained: Hold | $75 | $49.80 | +50.60% | 15 | May 5, 2026 | |
| SYRE Spyre Therapeutics | Rated: Buy | $50 → $90 | $80.79 | +11.40% | 14 | Apr 14, 2026 | |
| IONS Ionis Pharmaceuticals | Maintained: Buy | $100 | $73.28 | +36.47% | 42 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $30.40 | +48.03% | 4 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $5.71 | +92.64% | 27 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $25 | $12.35 | +102.43% | 1 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $2.50 | +60.00% | 25 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $15 → $60 | $27.57 | +117.63% | 27 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $6.97 | +186.94% | 26 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $4.08 | +243.14% | 27 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $1.56 | +220.51% | 19 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $3.09 | +29.45% | 9 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2.5 | $2.06 | +21.36% | 12 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2 | $0.151 | +1,224.50% | 21 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $11 → $0.1 | $0.0001 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 → $1 | $0.0315 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.50 | n/a | 13 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $30.28 | n/a | 7 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $45 → $30 | $2.26 | n/a | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $272 → $326 | $893.52 | n/a | 4 | Feb 2, 2021 |
Beam Therapeutics
Jun 4, 2026
Maintained: Buy
Price Target: $70
Current: $29.03
Upside: +141.13%
Intellia Therapeutics
May 12, 2026
Maintained: Hold
Price Target: $15
Current: $12.11
Upside: +23.86%
Metagenomi Therapeutics
May 11, 2026
Maintained: Buy
Price Target: $12 → $9
Current: $1.20
Upside: +650.00%
Cytokinetics
May 7, 2026
Maintained: Buy
Price Target: $95 → $105
Current: $70.15
Upside: +49.68%
Sarepta Therapeutics
May 7, 2026
Maintained: Buy
Price Target: $38
Current: $15.31
Upside: +148.20%
BeOne Medicines AG
May 7, 2026
Maintained: Buy
Price Target: $400
Current: $264.48
Upside: +51.24%
enGene Therapeutics
May 7, 2026
Downgraded: Hold
Price Target: $25 → $2
Current: $1.62
Upside: +23.46%
CRISPR Therapeutics AG
May 5, 2026
Maintained: Hold
Price Target: $75
Current: $49.80
Upside: +50.60%
Spyre Therapeutics
Apr 14, 2026
Rated: Buy
Price Target: $50 → $90
Current: $80.79
Upside: +11.40%
Ionis Pharmaceuticals
Apr 2, 2026
Maintained: Buy
Price Target: $100
Current: $73.28
Upside: +36.47%
Apr 2, 2026
Maintained: Buy
Price Target: $45
Current: $30.40
Upside: +48.03%
Mar 20, 2026
Maintained: Buy
Price Target: $11
Current: $5.71
Upside: +92.64%
Mar 11, 2026
Initiated Coverage: Buy
Price Target: $25
Current: $12.35
Upside: +102.43%
Mar 10, 2026
Maintained: Hold
Price Target: $4
Current: $2.50
Upside: +60.00%
Mar 9, 2026
Upgraded: Buy
Price Target: $15 → $60
Current: $27.57
Upside: +117.63%
Mar 4, 2026
Maintained: Buy
Price Target: $20
Current: $6.97
Upside: +186.94%
Feb 25, 2026
Reiterated: Buy
Price Target: $14
Current: $4.08
Upside: +243.14%
Jan 14, 2026
Maintained: Buy
Price Target: $5
Current: $1.56
Upside: +220.51%
Jan 13, 2026
Maintained: Hold
Price Target: $4
Current: $3.09
Upside: +29.45%
Jan 5, 2026
Maintained: Hold
Price Target: $2.5
Current: $2.06
Upside: +21.36%
Jun 25, 2025
Maintained: Hold
Price Target: $2
Current: $0.151
Upside: +1,224.50%
May 14, 2025
Downgraded: Hold
Price Target: $11 → $0.1
Current: $0.0001
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: $1.5 → $1
Current: $0.0315
Upside: n/a
May 6, 2025
Maintained: Buy
Price Target: $10
Current: $3.50
Upside: n/a
May 16, 2024
Rated: Hold
Price Target: n/a
Current: $30.28
Upside: n/a
Aug 16, 2023
Maintained: Hold
Price Target: $45 → $30
Current: $2.26
Upside: n/a
Feb 2, 2021
Maintained: Hold
Price Target: $272 → $326
Current: $893.52
Upside: n/a